ATAK™ Programs

 

2020

2021

2022

2023

PHASE Ia

Single arm open-label clinical trial of MT-1001 in subjects with advanced CD5+ expressing T cell lymphoma malignancies

Single arm open-label clinical trial of MT-102 in subjects with advanced HER2+ expressing gatric/GEJ malignancies

MT-101 Phase 1 Open Label Ascending Dose Study in Subjects with Peripheral T Cell Lymphoma (PTCL)

PHASE Ib

Single arm open-label clinical trial of MT-1001 in subjects with advanced CD5+ expressing T cell lymphoma malignancies

Single arm open-label clinical trial of MT-102 in subjects with advanced HER2+ expressing gatric/GEJ malignancies

MT-101 Phase 1 Open Label Ascending Dose Study in Subjects with Peripheral T Cell Lymphoma (PTCL)

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139